Better than Expected! Healthcare Giant J&J Grows Unstoppably and Aims for $100 Billion Revenue Mark!
Reading Time: 3 minutes
Forget the dusty image of the baby powder manufacturer. Johnson & Johnson (i)(JNJ) has radically shed its skin and presents itself as a highly profitable pharmaceutical powerhouse. While critics are still fixated on the legal hangovers, the healthcare giant delivered an operational fireworks display, exceeding all analyst forecasts in Q4 and targeting a historic revenue milestone of $100 billion for 2026. The pipeline is heating up, and the company is stronger than ever despite headwinds. Johnson & Johnson - High-Tech Medicine instead of...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
